Randomized clinical trials have demonstrated that progression-free survival (PFS) is longer with TKIs than with chemotherapy when EGFR mutations [2, 3] or the ALK rearrangement [4, 5]are present in advanced NSCLC. Here, ALK is linked to non-small cell lung carcinoma.